Q-omics provides the consensus-scored ZNF517 profile across patient tissues and cancer cell-line models. ZNF517 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF517 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ZNF517 RNA expression shows 19,687 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, COAD, and ACC as cancer lineages where ZNF517 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF517 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF517 survival associations across molecular data types. ZNF517 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF517 RNA expression–survival associations across cancer types. High ZNF517 expression shows unfavorable associations in KIRC, COAD and ACC, but favorable associations in SCLC, PAAD and LGG. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF517 RNA expression.
This table summarizes ZNF517 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF517. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF517 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, HNSC, KIRC and BRCA. The COAD box plot shows higher ZNF517 RNA expression in tumor versus normal tissue (log2 FC = +0.997, t-test p < 0.001).
This table shows molecular features associated with ZNF517 in patient tissues and cancer cell lines. In patient samples, ZNF517 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF517 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
